Modality
Small Molecule
MOA
TYK2i
Target
PD-L1
Pathway
Proteasome
Atopic DermHNSCCMDD
Development Pipeline
Preclinical
~Jan 2012
→ ~Apr 2013
Phase 1
~Jul 2013
→ ~Oct 2014
Phase 2
~Jan 2015
→ ~Apr 2016
Phase 3
~Jul 2016
→ ~Oct 2017
NDA/BLA
~Jan 2018
→ ~Apr 2019
Approved
Jul 2019
→ Jan 2030
ApprovedCurrent
NCT05059841
177 pts·MDD
2024-12→2030-01·Recruiting
NCT07029394
212 pts·Atopic Derm
2019-07→2027-11·Terminated
389 total pts2 indications
CompletedCurrentUpcoming
Catalysts (2)
2027-11-011.6y awayPh3 Readout· Atopic Derm
2030-01-053.8y awayPh3 Readout· MDD
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030
Approved
Termina…
Approved
Recruit…
Catalysts
Ph3 Readout
2027-11-01 · 1.6y away
Atopic Derm
Ph3 Readout
2030-01-05 · 3.8y away
MDD
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05059841 | Approved | MDD | Recruiting | 177 | VA |
| NCT07029394 | Approved | Atopic Derm | Terminated | 212 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET |